The Ethos Podcast

Our industry comes under great scrutiny and while complaints to the PMCPA are something we strive to avoid, they're a reality all companies face at some point or another, and they need to be prepared for. In this episode, we are joined by Natalie Whittle (Director of Code Development at the PMCPA) and John Dangerfield (Director of Governance, Process Assurance and Foundational Capabilities at MSD)...

In this episode, Dr Nick Broughton is joined by guest Paul Simms to put pharmaceutical marketing under the spotlight and question whether it is time to provoke our marketing playbook. If you've ever felt like pharma marketing could do with a shake up, this one's for you. In the discussion, they cover: 💡 What "provoking" pharma marketing means and why it's needed 📉 Where traditional marketing sti...

In this conversation, Dr Nick Broughton, Dr Sheuli Porkess and Ravi Pawa delve into the question: how do we make good decisions when the world of pharma is anything but black and white? A few themes we explore: 🔹 What does “good” decision-making actually look like? 🔹 Why understanding the bigger picture matters more than the finer details 🔹 The reality that absolute clarity is rare, and why the...

In this episode, Dr Nick Broughton sits down with Dr Ravi Pawa to unpack one of the most complex areas of pharmaceutical compliance: how the ABPI Code of Practice applies to congress activity. Together, they explore the questions keeping compliance teams and medical leaders up at night: Does Clause 8.2 mean UK clinicians at international congresses fall under the UK Code? How should companies hand...

Ethos Podcast: Do Companies Still Need Signatories in Pharma Compliance? This episode of the Ethos Pharmaceutical Ethics & Compliance Podcast explores a key question in the pharmaceutical industry: What is the point of having company signatories in today’s compliance landscape? With compliance reviews increasingly outsourced to specialist agencies and AI-powered tools becoming more common, we...